The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Switch maintenance and second-line therapy in G/GEJ cancer
Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, discusses the benefits of switch maintenance and early second-line therapies in the ARMANI trial (NCT02934464) in HER2-negative (HER2-) gastric/gastroesophageal junction (G/GEJ) cancer. Many patients were triple-negative, including PD-L1 low or absent expression, claudin 18.2 negative, and mismatch repair proficient, making them ineligible for targeted inhibitors. These patients could therefore benefit from the switching strategy. Implementing an early second-line therapy, rather than waiting for disease progression, could enhance its benefits. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
